肝静脉压力梯度在肝硬化患者中的应用进展

发布时间：2018-07-13 08:48

【摘要】：背景:无论何种原因引起的肝硬化,均会致使门静脉压力升高,门脉高压是引起肝硬化并发症的主要原因之一,而肝静脉压力梯度(hepatic venous pressure gradient HVPG)是目前预测肝硬化门脉高压症进展最可靠的金标准,并受到广大学者的关注及认可。目的:通过综述目前对肝静脉压力梯度在肝硬化患者中的研究,来更好的运用于临床并指导临床治疗。方法:以“肝静脉压力梯度,门静脉高压,肝硬化,静脉曲张出血,腹水,肝癌”为关键词进行检索,找出国内外有关肝静脉压力梯度在肝硬化患者中研究的文献,并对其作出总结。结论:目前有大量关于肝静脉压力梯度在肝硬化患者中的研究文献,综合这些研究结果表明,肝静脉压力梯度可以用于帮助评估肝硬化患者的危险程度,指导临床治疗,评估药物疗效,预测肝硬化进展与治疗等多个方面,已在肝硬化患者的临床运用当中有着不可或缺的地位。
[Abstract]:Background: portal hypertension is one of the main causes of cirrhotic complications, regardless of the cause of cirrhosis. The hepatic venous pressure gradient (hepatic venous pressure gradient) is the most reliable gold standard for predicting the progression of portal hypertension in liver cirrhosis. Objective: to review the current studies of hepatic venous pressure gradient in patients with liver cirrhosis to better use in clinical and guide clinical treatment. Methods: "Hepatic vein pressure gradient, portal hypertension, liver cirrhosis, varicose hemorrhage, ascites, liver cancer" were used as the key words to search for the literatures on the study of hepatic vein pressure gradient in patients with liver cirrhosis at home and abroad. And make a summary of it. Conclusion: there are a large number of literatures on hepatic venous pressure gradient in patients with liver cirrhosis. These results indicate that hepatic vein pressure gradient can be used to assess the risk level of patients with liver cirrhosis and to guide clinical treatment. Evaluation of drug efficacy, prediction of progress and treatment of liver cirrhosis have played an indispensable role in the clinical application of liver cirrhosis patients.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R575.2

【参考文献】